HIV & AIDS in the Transgender Community: Risks & Prevention Resources

Transgender and gender-diverse people face a disproportionately high burden of HIV. Global meta-analyses estimate HIV prevalence among transgender women at ~19%—49x higher than the general adult population. Transgender men also face elevated risk, though data are more limited. This disparity is driven by structural, not individual, factors.

Structural Drivers of HIV Risk

• Discrimination & stigma: In housing, employment, education, healthcare, and legal systems. Trans people experience high rates of job loss, housing instability, and healthcare denial—creating economic vulnerability and care avoidance.
• Poverty & economic marginalization: Higher rates of poverty limit access to housing, nutrition, healthcare, and prevention tools (PrEP, condoms).
• Criminalization & policing: Sex work criminalization, "walking while trans" profiling, and incarceration disrupt care and increase exposure risk.
• Healthcare barriers: Lack of gender-affirming providers, insurance exclusions, misgendering, and trauma in medical settings lead to delayed/avoided care.
• Substance use: Higher rates of alcohol/drug use—often coping with minority stress—can impair judgment around sexual safety and medication adherence.
• Sex work: Overrepresentation due to employment discrimination; increases exposure risk if not done safely with full prevention access.
• Gender-affirming care gaps: Lack of access to hormones/surgery may increase dysphoria and risk behaviors; conversely, gender-affirming care improves mental health and HIV outcomes.

Risk Reduction Strategies

• Regular HIV/STI testing: At least annually; more frequently (every 3 months) if sexually active with multiple partners or other risk factors. Early diagnosis enables early treatment (U=U).
• Consistent condom/lubricant use: For anal and vaginal sex. External and internal condoms available.
• Hepatitis A & B vaccination: Protects liver health; coinfection worsens HIV outcomes.
• PrEP (pre-exposure prophylaxis): Daily oral TDF/FTC or TAF/FTC, or injectable cabotegravir every 2 months. Highly effective for trans people; discuss with knowledgeable provider about interactions with gender-affirming hormones (minimal for TDF/FTC; monitor renal function).
• PEP (post-exposure prophylaxis): Emergency 28-day ART course within 72 hours of potential exposure.
• Gender-affirming hormone therapy: Improves mental health, reduces risk behaviors; integrate with HIV care.
• Seek community support: Trans-led organizations offer navigation, housing, legal aid, healthcare linkage, peer support. Examples: Trans Lifeline, local trans health programs, CDC-funded CBOs.

Trans people are resilient. With affirming care, structural barriers removed, and access to biomedical prevention, HIV incidence in trans communities can plummet. Advocacy for trans rights is HIV prevention.